Mylan buys rights to Pfizer respiratory drug
PITTSBURGH — Mylan has acquired rights to an experimental respiratory drug made by Pfizer, Mylan said Wednesday.
The drug maker said it had bought exclusive worldwide development, manufacturing and commercialization rights to the drug, which was not named, but was described as a long-acting muscarinic antagonist about to enter phase-2b, or mid-stage, clinical trials. Mylan said it would develop the drug into combination therapies and that they would use a multidose dry powder inhaler technology, also licensed from Pfizer.
"This acquisition further expands Mylan’s growing respiratory franchise, building upon the products we already have in development, such as our generic Advair program and our combination product for the treatment of chronic obstructive pulmonary disease," Mylan CEO Heather Bresch said. "By adding a novel LAMA compound to our capabilities, we will have the opportunity to bring additional combination products to market, including triple-combination therapies, and further differentiate Mylan as a leader in this important therapeutic area."
A&P inks deal with Innovatix to expand specialty pharmacy business
NEW YORK — Grocer A&P, which operates more than 300 stores across six states, has signed a three-year agreement with Innovatix, whereby it will serve as A&P’s exclusive provider of specialty pharmacy services.
“We are pleased that A&P has joined our Specialty Pharmacy Management program,” stated Innovatix president and CEO John Sganga. “Innovatix is confident that its experience collaborating with key stakeholders in the specialty market, together with its ability to manage complex purchasing data, will prove valuable as A&P grows its specialty pharmacy business.”
Through Innovatix Specialty Pharmacy Management, a turnkey and à la carte solution for retail pharmacies to expand into the specialty market, A&P will receive access to specialty medications, as well as back office services including dispensing, data management, clinical and reimbursement support and patient financial assistance.
“We are very excited about our new partnership with Innovatix to provide comprehensive Specialty Medication service to our patients,” added Robin Page, VP pharmacy at A&P. “The expertise and resources that Innovatix offers will assist us with providing product as well as full medication therapy management support for our patients.”
Mylan, Banner settle cancer drug lawsuit with Eisai, Valeant
PITTSBURGH — Mylan and a partnering company will be able to sell a generic version of a cancer drug starting in summer 2015, under a court settlement announced Tuesday.
Mylan said that it and Banner Pharmacaps had reached a settlement agreement with Eisai and a subsidiary of Valeant Pharmaceuticals International to resolve a lawsuit filed over their generic version of Targretin (bexarotene) capsules in the 75-mg strength. The drug is used to treat certain forms of T-cell lymphoma.
Under the agreement, Mylan and Banner can start selling a generic version of Targretin starting in July 2015. Targretin in the 75-mg strength had sales of about $53.6 million during the 12-month period that ended in September, according to IMS Health.